Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01763164
Title	Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Novartis\|Novartis Pharmaceuticals
Indications	melanoma
Therapies	Dacarbazine Binimetinib
Age Groups:	adult
Covered Countries	USA \| TUR \| SWE \| SVK \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG